Should pharma Companies avoid Mobile apps? and DigitalHealth

Its easier to say current mobile app model is broken, but at same time they still offer advantages atleast in the first few years when a drug enter the market. But the truth is these apps seldom becomes useful for the larger audience.

Pharma Mobile App Problems

Study among 1814 physicians in 25 specialties shows often pharmaceutical sales reps show medical information that physicians have seen already through other digital and non-digital channels, and most often those digital channels and content are often not even created by pharma companies

Thats because current Pharma Digital projects often run in isolation to a range of existing patient/physician outreach channels, including: e-mail marketing, rep-triggered emails, web-events (webcasts, of conferences and meetings), videos, self-guided e-detailing, remote detailing, product websites, treatment and diagnostic tools (apps), training courses (CME)

Digital to Beyond the Pill

Most pharma companies already uses a central system to manage their websites but nothing of similar nature exists for other digital channels especially the mobile apps. The early concepts of “Digital Factory” where confined to merely outsourcing resources involved in infrastructure and content development to a single IT/BPO vendor. The mobile app Factory need to become essential part of the Digital Pharma 2.0 changes.

Most of the DigitalHealth apps have failed or have seen usage metrics going down after initial hype. Most #digitalhealth apps and #startups fail after initial success because, while we cherish our health we hate being reminded about our sickness.

Read the rest of the Original article at Linkedin 

France to invest €670 million euros for Genomics and Personalized Medicine

Government of France Announce plans to invest €670 million euros or ($760.8 million) for Genomics and Personalized Medicine which will see it establish 12 genome sequencing centers and two national centers for genomic expertise and data analysis. The program would initially focus on cancer, diabetes and rare diseases but after 2020 would expand to include common diseases.

This investment by France follows the release on Wednesday of a report by medical experts examining the possibility of France widening access to genetic medicine within 10 years. A key objective in the report for the first 10 years of the programme is to prepare for the integration of genomic medicine into the normal course of patient care in the country, which means sequencing about 235,000 genomes per year by 2020.

Health Minister Marisol Touraine said Investment in the five year initiative will also come from industry. He also expected Companies like Google, Amazon, Apple and Facebook are interested in the growing genomic medicine sector

Several European countries have already begun to integrate genomic medicine into their health systems and there are large scale genomic initiatives in the UK, US and China. China has even recently announced a Precision Medicine Cloud

 

 

Predictive Analytics for Patient Adherence

The New Medicine Service (NMS) offered by Engalnd’s  NHS community pharmacies came into effect since 1st October 2011. NMS is a patient adherene service and focuses on patients with long term conditions that have been prescribed new medicines.

It is hoped that NMS will lead to the following outcomes:

  • improve medicines adherence
  • increase patient engagement with their condition and medicines, which will support them in making decisions about their treatment and self management
  • reduce medicines wastage
  • reduce hospital admissions due to adverse events associated with medicines
  • increase reporting of medicine adverse reactions by pharmacists and patients
  • positive patient assessments
  • provide evidence base on the effectiveness of the service
  • enable the development of outcome and/or quality measures for community pharmacy

But the Service since launch has seen severe criticism from pharmacists’ over several issues, especially how the pharmacist is re-imbursed for the providing the service which also involved patient counselling.

The answer perhaps can be found by applying predictive analytics to identify patients who are more likely to deviate or other likely to exhibit non-compliance in adhering to the prescription.

Express Scripts has developed a set of proprietary computer models that predict, up to a year in advance, which patients are at risk of not following through on their prescribed drug therapy. details

FICO an analytics service provider also provides medication adherence ranking based on predictive analytics details

AstraZeneca Announce Real-World Evidence Data Collaboration

AstraZeneca Pharmaceuticals LP (NYSE: AZN) and HealthCore, Inc., the health outcomes research subsidiary of WellPoint, Inc. (NYSE: WLP), announced a collaborative agreement to conduct real-world studies designed to determine how to most effectively and economically treat disease

Unlike controlled clinical trials, real-world evidence studies use observational data such as electronic medical records, claims information and patient surveys. By examining data associated with the delivery of care, real-world analyses can assess treatment impact on hospital length of stay, readmissions, overall health status, cost of care and other key evidence-based outcomes.

A leader in health outcomes research, HealthCore maintains the largest data environment in the nation. HealthCore’s near real-time, fully-integrated data environment combines medical, pharmacy, laboratory results and other information drawn from 36 million enrollees in local Blue Cross and/or Blue Shield plans with concentrated populations in 16 states.

 

personalized medicine might be making drug development more complicated

According to a new report from the Tufts Center for the Study of Drug Development at Tufts University 12 to 50 percent of the drugs companies are developing, depending on the company, involved a personalized medicine approach.

The Tufts report is based on a survey of 25 companies, large and small, to which 16 companies responded, as well as interviews with representatives of 13 companies.

Relatively few drugs are now accompanied by such so-called companion diagnostic tests. They are most common in oncology. The breast cancer drug Herceptin, for instance, is given only to women whose tumors have an abundance of a protein called Her2.

According to the report Other key therapeutic areas in which personalized medicine is making headway include cardiovascular, central nervous system, and immunologic therapies, whereas personalized medicine development is just getting started for metabolic and respiratory therapies, as well as virology.

 

Paper instead ‘chips’ may be used as medical testing devices to fight disease

George Whitesides, a Harvard chemistry professor has designed technology in which patients’ blood is dropped on a piece of paper, and water-repellent ink resembling that of a comic book creates diagnostic colors on the other side, CNN reports. The technology may be incorporated into mobile phones, according to CNN.

Whitesides’ prototype allows for testing of STDs and non-sexually transmitted diseases, including HIV, malaria, tuberculosis, hepatitis and gastroenteritis.

 

UK’s Medical Research Council grants Clinical Research consortium $6.4 million to develop chips & software to use mobile phones/PCs as testing devices for sexually transmitted disease (STD)

UK’s Medical Research Council grants a Clinical Research consortium $6.4 million to develop chips & software to use mobile phones/PCs as testing devices for sexually transmitted disease (STD)

If successful individuals will drop their blood, urine or saliva on a mobile chip, which they then insert into a mobile phone or PC. Software on the phone or PC then delivers a diagnosis, schedules a clinic appointment or sends an electronic prescription to a pharmacy. Consumers will be able to purchase the chips in vending machines or at a local pharmacy

Oracle starts the Oracle Health Sciences Institute (OHSI), in partnership with Sun Labs

The Institute is focused on research that will accelerate IT innovation to advance personalized medicine and the delivery of safe and effective   treatments and health care services to patients around the globe. OHSI will work in tandem with academic research centers, focusing on a targeted set of research areas fundamental to the R&D and health care delivery challenges facing health sciences organizations today. Research priorities currently include: artificial intelligence and semantic technology; genomic, genetic and phenotypic data analysis; data mining to support optimization of clinical trials; and predictive algorithms and other technology to advance patient safety and provide advanced decision support at the point of care.Academic institutions interested in collaborating with OHSI in these focus areas should contact OHSI representatives at Oracle http://linkd.in/bXf98c
Oracle starts Oracle Health Sciences Institute (OHSI), in partnership with Sun Labs. This is exiting news and I hope we get to see the participation of Open Source Drug Development Network (OSDD) and initiative by CSIR India earlier supported by Sun Microsystems

How useful would be the Single-patient clinical trials for improving the hopes of Personalized medicine

Single patient Clinical Trial are not new idea, FDA did not focus since such trial canot prove the efficacy and safety of medicine over a large pool of patient with sufficient data. But I was forced to re-think after reading the article http://www.technologyreview.in/biomedicine/12537/ why cant we use the the concept mentioned in to overcome the ethical and other challenges in current mode of trials.

So I decided to ask the question to the linkedin audience http://www.linkedin.com/answers/technology/biotech/TCH_BIO/667022-9262868?browseIdx=0&sik=1272969161323&goback=.amq

Oracle and Inforsense Integrating Clinical And Genomics Data for Personalized Medicine

BIO-IT WORLD COVERAGE ON INTEGRATING CLINICAL AND GENOMICS DATA AND PLATFORMS FOR PERSONALIZED MEDICINE

The March-April 2009 issue of Bio-IT World features Dana-Farber Cancer Institute cover story on integrating clinical and genomics data including details on the organization’s work with Oracle and InforSense, as well as a byline article on platforms for personalized medicine by Neil de Crescenzo, senior vice president and general manager, Oracle Health Sciences.

Integrating Clinical and Genomics Data

The cover story of Bio-IT World highlights the groundbreaking work of Dana-Farber Cancer Institute’s (DFCI) John Quackenbush, professor of biostatistics and computational biology, who at the vanguard of translational medicine is bridging genomics, bioinformatics, and IT in an effort to shed light on cancer biology. With assists from Oracle and InforSense, Dana-Farber’s John Quackenbush is finding ways to mine vast patient data collections to better understand human cancer. “Our successful collaboration with Oracle and InforSense has put us in a position to think about reaching beyond DFCI and gradually pulling in a lot of Harvard’s multi-institutional spores and their data collections,” Quackenbush says.

To read the complete Bio-IT World cover story article on integrating clinical and genomics data, click here.

Platforms for Personalized Medicine
This article by Neil de Crescenzo, senior vice president and general manager, Oracle Health Sciences discusses personalized medicine and how integrating clinical information and R&D data can ensure success. Personalized medicine promises to improve understanding of the mechanisms of disease and permit more effective patient care. It also stands to transform the focus of the pharmaceutical industry as the cost of drug discovery exceeds $1 billion, and established blockbuster drugs lose patent protection. Although it holds great promise, realizing the benefits of personalized medicine presents significant challenges for life sciences companies, particularly surrounding the integration of research and clinical data – both within and between life sciences companies and healthcare organizations.
To read the complete Bio-IT World article on platforms for personalized medicine, click here.

Deadline for Personal Genomics Companies

State of New York has issues warning against Personal genomics companies , after they have received many complaints. Now the State of California Department of Helath (CDPH) is trying to keep consumer genetic testing companies from offering their services to the state’s residents and last week sent letters to 13 firms saying they are violating state law. The companies have time till today June 24 to respond to the notice. While New York State warned several companies that genome tests could not be performed on samples from New York residents without formal state approval.

CDPH requirements mandate that

  1. Any business offering genetic tests to California residents must be licensed as a clinical laboratory in California
  2. The laboratory must have must have a CLIA certificate for laboratory testing
  3. All genetic tests must be ordered by a licensed physician

The 3rd part of the requirements mean the end of DIY genetic testing and more headches for companies in coming weeks.

Google-backed 23andMe and Navigenics are also included in the list of companies that received the notice The major companies, including 23andMe, Navigenics, and Decode Genetics have issued statements confirming that theya re using CLIA registered laboraotries for the testing DNA genotyping. 23andMe partners with Illumina, while Navigenics collaborates with Affymetrix.

Steven Murphy compared these companies to napster check out his blog post1 post2 on this subjetcs. He is certainly not likely to be excited to learn that 23andMe has launched a wiki page called 23andWe to recruit its customers to participate in studies trying to shed additional light on genetic predispositions for certain diseases and adverse drug reactions.

23andMe has maintained that it is not selling a medical service but rather giving people access to their genetic information. They company prefers to call its 23andWe study participants “customers” and not “patients,” . Smart move but lets see if CDPH is going to buy that argument.

But today 23andMe shot back to CDPH that they’ll be doing neither cease nor desist. We believe we are in compliance with California law and are continuing to operate in California at this time,” the company said in a statement released to Wired.com

The company has has argued that the testing they provide isn’t a prevention aid, but merely offers “individuals contextual information about their genetic makeup, including ancestry and applicable scientific research.”

Microarrays in Personalized Medicine- $200M-US Aided Personalized Medicine Program

I have written quiet often about this subject and companies that promises solution for personalized medicine. especially the use of genomics information in organ transplant patients and cancer treatment. XDx and Genomic Health are two such companies . XDX has applied microarray, to monitor the immune system, with the help of Gene expression to address the challenge of balancing the risk of acute cellular rejection against the known adverse effects of immunosuppressants; especially inexpression testing for patients with heart transplants. Genomic Health provides individualized genomic profiling of tumor tissue may help improve cancer management.

personalized medicine is still dismissed of by many as the cost are still high, and there are very few trained physicians who can use this extra information for better clinical outcome.

US institutes Biodesign Institute at Arizona State University, Fred Hutchinson Cancer Center Translational Genomics Research Institute (TGen), the Institute for Systems Biology, and the Partnership for Personalized Medicine will help the government of Luxembourg start a three-pronged, $200 million-plus biomedical initiative focused on harnessing genomics technologies to study human health problems.

For those who wants to cry foul that genomic information can lead to discrimination against individuals by insurance companies or others can take solace on GINA . In may 21.2008 President  George Bush has signed into law the Genetic Information Nondiscrimination Act (GINA) that will protect Americans against discrimination based on their genetic information when it comes to health insurance and employment.

The most immediate benefit of GINA is to remove barriers to identifying individuals at high risk for diseases due to genetic mutations before the onset of the disease

personalized, safety alerts about your medication

A service launched by quintiles claims to be one of the first to provide post launch drug safety information about drugs directly to any one who is using them.  iGuard is a web-based services that will help you take medication safety without the help of  healthcare professionals.

You can register on the site for free and record all the drugs you are using, along with  general health profile. When the FDA issues advisories and other safety notices for some 20,000 different marketed drugs, or when new research emerges about drugs or drug interactions that may affect them, iGuard members taking those drugs will get an e-mail alert.

The warning system uses a scale of 1 to 5 and is color-coded in a way that was inspired by the U.S. government’s homeland security alerts.

t’s impossible to gauge how many drugs will be given a “1,” which means suitable for widespread use, or a “5,” which iGuard says should be more carefully considered. Lipitor, for the record, gets a “2” rating from iGuard.

CombiMatrix Molecular Diagnostics Launches Microarray Test for Detection of Autism Spectrum Disorder

CombiMatrix  has completed the clinical validation of the  BAC array CGH based clinical microarray tests. ATScan is designed to detect known genomic copy-number variations  associated with Autism Spectrum Disorder and this test is now available to physicians and consumers.

Wireless ID Skin Patch Technology for Personal diagnostics using cell phones

Medgadget reports about the IP Development Company Gentag and Frank Sammeroff working on a new smart, wireless ID skin patch technology that aims to reduce medical errors in hospitals worldwide,

 

This patented, non-invasive solution combines disposable skin patches with RFID tags and cellphones, enabling doctors and nurses to use their handsets or wireless PDAs to update medical charts, time of patient visit and drug administration.

 

Not only that, it can be used to warn about possible drug interactions prior to drug delivery on-the-spot – a great tool for a doctor who has been working for 2 shifts in a row without stopping.

<!–

–>

Medicine OnDemand

Move over the TeleMedicine and the usual chutzpah, Yesd Web2.0 is a bubble thats going to burst, but in healthcare field strangled by Insurannce companies, web2.0 is giving a whiff of relief to some people atleast , How!

 WebMD ,MayoClinic ,eMedTV are few site that offers to help you through videos, blogs and other channels

Officials at the Department of Health and Human Services have linked the Health records to the WebMD site, With companies like google and Microsoft coming into the same field it might bring some changes in the way we see medicla treatment in the next 5-10 years, that after the inital euphoria subsides and companies starts to build comercially viable services.
                                                                                         

Gene Logic sells in genomics division

It hardly a week I have wrote about acquisition and mergers , it seems the rain is noit going to stop any time soon, the latest one , to give away the home plate is Genelogic agreeing to sell its genomics division to India HQ Ocimum Biosolutions subject to the authorization of the transaction at a special meeting of shareholders of Gene Logic.

This is a transforming event of significant strategic proportion,” said Charles L. Dimmler, III, President and Chief Executive Officer of Gene Logic.

Genelogic bought its preclinical division from TherImmune, a Gaithersburg company, in April 2003 for $51 million which was sold to Bridge Pharmaceuticals for $15 Million,

Gene Logic Inc said it agreed to sell its Genomics assets to Ocimum Biosolutions Ltd for $10 million in cash. Under the terms of the Ocimum sale agreement, Gene Logic retains full rights in perpetuity to utilize the existing information data bases of its former Genomics business as key elements in building its emerging drug repositioning and development business. Furthermore, the Company will retain specified assets related to molecular diagnostics and will continue to explore strategic alternatives for these assets

The sale is part of the Genelogic new strategy to focus on to build drug repositioning and development business which was decided last year.

Ocium will assume certain liabilities associated with the Genomics assets and business and will pay Gene Logic $7 million at closing and $3 million payable in a promissory note due 18 months from closing.

The purchase includes Gene Logic’s Knowledge Products business including the The BioExpress® System a continually growing genomic database of gene expression data and associated clinical information from over 18,000 human and animal tissues and cell line samples. ToxExpress® a toxicogenomics reference database.

Ocimum will continue to operate the business out of the current state-of-the-art laboratory facility of Gene Logic in Gaithersburg, Maryland.

Oracle Openworld 2007- Personalized Genomics session

Its the time -Personalized Genomics

Advances in genetic information and laboratory technologies mean new ways to diagnose disease and determine patient risk. The wealth of genetic information makes it harder to provide meaningful information. During Oracle OpenWorld 2007 Oracle is presenting how laboratory information systems principles and Oracle customer relationship management and enterprise resource planning applications weave together, using Oracle Fusion Middleware to create a unique platform for translational medicine.


Click here to register now.

Oracle OpenWorld

Experience Innovation. November 11-15, 2007, San Francisco, Moscone Center.

As the Life Sciences industry continues to grow and change, Oracle is there to help you learn, adapt, and succeed.

Please join us this fall in San Francisco as we address some of the biggest challenges facing the Life Sciences industry and how Oracle is prepared to meet those challenges.

Session highlights include:

  • Product Lifecycle Management—At this session, learn how Oracle’s Agile product lifecycle management solutions for Life Sciences improve new product introduction cycle times, reduce direct material and operating costs, and enable cost-effective compliance.
  • A Cure for Clinical Trials: From Data Capture to Submission—Approximately 80,000 clinical trials are being conducted in the United States at any given time. More than half of them are behind schedule by one to six months. Clinical trial sponsors hope to reduce this and other costly delays through the use of IT. Hear how the latest enhancements in Oracle’s industry-leading Life Sciences applications are streamlining the process of data capture, management, analysis, and reporting.
  • Enabling Personalized Medicine in Research and Development—The sequencing of the human genome is yielding exciting new tools to help physicians tailor treatments to individuals and their diseases. This powerful new capability, called personalized medicine, holds great potential to improve patient health. Learn how Oracle’s technology is enabling personalized medicine and improving efficiencies and outcomes in clinical development.

Click here for a full list of Life Sciences sessions.

Registration is now open for the most exciting technology and business conference of the year.
Registration fees go up soon So don’t wait—act now to save $900.

Click here to register now. To receive your special discount, select a registration category and enter keyword: ORF at the bottom of step 2 of the registration process.

THE INFORMATION COMPANY
Sponsor Logos
Oracle Corporation
Copyright © 2007, Oracle Corporation and/or its affiliates. All rights reserved.  

Pharmacogenomics has started

IT been a long time since my last post, So I thought of catching up with other blogger before going to do anything myslef. So here is what got my attention from Alla Katsnelson blog on the scientist magazine  that  USFDA approved updated labeling for the widely used blood-thinning drug, Coumadin, to explain that people’s genetic makeup may influence how they respond to the drug.

so whats going to be good for common man, the next time (not very soon) you are going to be under treatment of a controversial drug you might get to know how your genetics makeup can affect the treatment, thats going to be a good relief especially cancer patients and those who undergo HRT

while Frost&Sullivan reports in its latest industry update that  genomics platforms that are too inefficient and expensive for ultra-high throughput comprehensive genome-wide analysis are hindering the realization of personal genomics.

Gone in 60seconds-

Personalized Medicine in 60 Seconds

Bioinformatics was a BOOM its was predicted to be next big thing, yet the industry which had hundereds of fragmented mom and pop kind small companies are now under mergers and acquisitions, Does everyone got their money back.

Bioinformatics is yet to become the big Billion billion Dollar, and on the door step the next big thing is ready for its journey

Personalized Medicine in 60 Seconds is the article published in Wired magazine

%d bloggers like this: